RT Journal Article
T1 Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study.
A1 Muñoz-Gómez, Ana
A1 Fernández-Cruz, Ana
A1 Lavilla-Olleros, Cristina
A1 Giner-Galvañ, Vicente
A1 Ausín-García, Cristina
A1 Wikman, Philip
A1 Bendala-Estrada, Alejandro D
A1 Vargas, Juan A
A1 Rubio-Rivas, Manuel
A1 Laureiro, Jaime
A1 Fernández-Bermúdez, Daniel
A1 Buonaiuto, Verónica A
A1 Arenas de Larriva, Antonio P
A1 Pascual-Pérez, María de Los Reyes
A1 Alcalá-Pedrajas, José N
A1 Labirua-Iturburu Ruiz, Ane
A1 Hernández-Milián, Almudena
A1 Gómez Del Mazo, Marta
A1 Antequera, Beatriz
A1 Mella-Pérez, Carmen
A1 Navas-Alcántara, María de la Sierra
A1 Soto-Delgado, Juan F
A1 Gámez-Mancera, Rosa M
A1 Sardiña-González, Cristina
A1 Meijide-Míguez, Héctor
A1 Ramos-Rincón, José M
A1 Gómez-Huelgas, Ricardo
A1 On Behalf Of The Semi-Covid-Network, 
K1 COVID-19
K1 SARS-CoV-2
K1 corticosteroids
K1 mortality
AB We aimed to determine the impact of steroid use in COVID-19 in-hospital mortality, in a retrospective cohort study of the SEMICOVID19 database of admitted patients with SARS-CoV-2 laboratory-confirmed pneumonia from 131 Spanish hospitals. Patients treated with corticosteroids were compared to patients not treated with corticosteroids; and adjusted using a propensity-score for steroid treatment. From March-July 2020, 5.262 (35.26%) were treated with corticosteroids and 9.659 (64.73%) were not. In-hospital mortality overall was 20.50%; it was higher in patients treated with corticosteroids than in controls (28.5% versus 16.2%, OR 2.068 [95% confidence interval; 1.908 to 2.242]; p = 0.0001); however, when adjusting by occurrence of ARDS, mortality was significantly lower in the steroid group (43.4% versus 57.6%; OR 0.564 [95% confidence interval; 0.503 to 0.633]; p = 0.0001). Moreover, the greater the respiratory failure, the greater the impact on mortality of the steroid treatment. When adjusting these results including the propensity score as a covariate, in-hospital mortality remained significantly lower in the steroid group (OR 0.774 [0.660 to 0.907], p = 0.002). Steroid treatment reduced mortality by 24% relative to no steroid treatment (RRR 0.24). These results support the use of glucocorticoids in COVID-19 in this subgroup of patients.
SN 2077-0383
YR 2021
FD 2021-10-13
LK https://hdl.handle.net/10668/25893
UL https://hdl.handle.net/10668/25893
LA en
DS RISalud
RD Apr 17, 2025